Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

NCT01101841 is registered in ClinicalTrials.gov with Noven Therapeutics as lead sponsor.

NCT NCT01101841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
Lead sponsor
Noven Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
November 30, 2011
Enrollment
570 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hot flashes